Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects.

Upreti VV, Keung CF, Boulton DW, Chang M, Li L, Tang A, Hsiang BC, Quamina-Edghill D, Frevert EU, Lacreta FP.

Clin Drug Investig. 2013 May;33(5):365-74. doi: 10.1007/s40261-013-0075-z.

PMID:
23549864
2.

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole.

Patel CG, Li L, Girgis S, Kornhauser DM, Frevert EU, Boulton DW.

Clin Pharmacol. 2011;3:13-25. doi: 10.2147/CPAA.S15227. Epub 2011 Jun 22.

3.

Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.

Boulton DW, Li L, Frevert EU, Tang A, Castaneda L, Vachharajani NN, Kornhauser DM, Patel CG.

Clin Pharmacokinet. 2011 Apr;50(4):253-65. doi: 10.2165/11584350-000000000-00000.

PMID:
21348538
4.

The synthesis and structure-activity relationship studies of selective acetyl-CoA carboxylase inhibitors containing 4-(thiazol-5-yl)but-3-yn-2-amino motif: polar region modifications.

Xu X, Weitzberg M, Keyes RF, Li Q, Wang R, Wang X, Zhang X, Frevert EU, Camp HS, Beutel BA, Sham HL, Gu YG.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1803-7. Epub 2006 Dec 21.

PMID:
17234407
5.

Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.

Rohde JJ, Pliushchev MA, Sorensen BK, Wodka D, Shuai Q, Wang J, Fung S, Monzon KM, Chiou WJ, Pan L, Deng X, Chovan LE, Ramaiya A, Mullally M, Henry RF, Stolarik DF, Imade HM, Marsh KC, Beno DW, Fey TA, Droz BA, Brune ME, Camp HS, Sham HL, Frevert EU, Jacobson PB, Link JT.

J Med Chem. 2007 Jan 11;50(1):149-64.

PMID:
17201418
6.

Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors.

Sorensen B, Winn M, Rohde J, Shuai Q, Wang J, Fung S, Monzon K, Chiou W, Stolarik D, Imade H, Pan L, Deng X, Chovan L, Longenecker K, Judge R, Qin W, Brune M, Camp H, Frevert EU, Jacobson P, Link JT.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):527-32. Epub 2006 Oct 7.

PMID:
17070044
7.

Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.

Richards S, Sorensen B, Jae HS, Winn M, Chen Y, Wang J, Fung S, Monzon K, Frevert EU, Jacobson P, Sham H, Link JT.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6241-5. Epub 2006 Sep 26.

PMID:
17000111
8.

Adamantane 11-beta-HSD-1 inhibitors: Application of an isocyanide multicomponent reaction.

Sorensen B, Rohde J, Wang J, Fung S, Monzon K, Chiou W, Pan L, Deng X, Stolarik D, Frevert EU, Jacobson P, Link JT.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):5958-62. Epub 2006 Sep 25.

PMID:
16996734
9.

Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity.

Clark RF, Zhang T, Xin Z, Liu G, Wang Y, Hansen TM, Wang X, Wang R, Zhang X, Frevert EU, Camp HS, Beutel BA, Sham HL, Gu YG.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):6078-81. Epub 2006 Sep 14.

PMID:
16973360
10.

Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors.

Gu YG, Weitzberg M, Clark RF, Xu X, Li Q, Zhang T, Hansen TM, Liu G, Xin Z, Wang X, Wang R, McNally T, Zinker BA, Frevert EU, Camp HS, Beutel BA, Sham HL.

J Med Chem. 2006 Jun 29;49(13):3770-3. Erratum in: J Med Chem. 2006 Aug 10;49(16):5028. Zinker, Bradley A [added]; Frevert, Ernst U [added]; Camp, Heidi [corrected to Camp, Heidi S].

PMID:
16789734
11.

A self-contained 48-well fatty acid oxidation assay.

Wang X, Wang R, Nemcek TA, Cao N, Pan JY, Frevert EU.

Assay Drug Dev Technol. 2004 Feb;2(1):63-9.

PMID:
15090211
12.

Microarrayed compound screening (microARCS) to identify activators and inhibitors of AMP-activated protein kinase.

Anderson SN, Cool BL, Kifle L, Chiou W, Egan DA, Barrett LW, Richardson PL, Frevert EU, Warrior U, Kofron JL, Burns DJ.

J Biomol Screen. 2004 Mar;9(2):112-21.

PMID:
15006134
13.

Adenovirus-mediated expression of a naturally occurring Asp905Tyr variant of the glycogen-associated regulatory subunit of protein phosphatase-1 in L6 myotubes.

Rasmussen SK, Hansen L, Frevert EU, Cohen PT, Kahn BB, Pedersen O.

Diabetologia. 2000 Jun;43(6):718-22.

PMID:
10907117
14.
15.

Regulation of early events in integrin signaling by protein tyrosine phosphatase SHP-2.

Oh ES, Gu H, Saxton TM, Timms JF, Hausdorff S, Frevert EU, Kahn BB, Pawson T, Neel BG, Thomas SM.

Mol Cell Biol. 1999 Apr;19(4):3205-15.

16.

Targeting of constitutively active phosphoinositide 3-kinase to GLUT4-containing vesicles in 3T3-L1 adipocytes.

Frevert EU, Bjørbaek C, Venable CL, Keller SR, Kahn BB.

J Biol Chem. 1998 Sep 25;273(39):25480-7.

17.

Evidence against a direct effect of leptin on glucose transport in skeletal muscle and adipocytes.

Zierath JR, Frevert EU, Ryder JW, Berggren PO, Kahn BB.

Diabetes. 1998 Jan;47(1):1-4.

PMID:
9421367
18.
21.

Markers of bone metabolism during short-term administration of thyroxine in healthy volunteers.

Frevert EU, Biester A, Müller MJ, Schmidt-Gayk H, von zur Mühlen A, Brabant G.

Eur J Endocrinol. 1994 Aug;131(2):145-9.

PMID:
8075783
22.

Studies on the subcellular mechanisms mediating the negative estradiol effect on GnRH-induced LH-release by rat pituitary cells in culture.

Emons G, Frevert EU, Ortmann O, Fingscheidt U, Sturm R, Kiesel L, Knuppen R.

Acta Endocrinol (Copenh). 1989 Sep;121(3):350-60.

PMID:
2552726

Supplemental Content

Loading ...
Support Center